Indcution chemotherapy and radiotherapy vs. induction and simultaneous radiochemotherapy in inoperable stage III NSCLC. Update on BROCAT study CTRT 99/97 Source: Eur Respir J 2006; 28: Suppl. 50, 833s Year: 2006
Efficacy of induction chemotherapy and following simultaneous radiochemotherapy versus induction chemotherapy and radiotherapy alone in inoperable NSCLC (Stage IIIA/IIIB): update of CT/RT 99/97 Source: Annual Congress 2004 - Management of lung cancer and innovative therapies Year: 2004
Induction chemotherapy and simultaneous radiochemotherapy or radiotherapy in inoperable NSCLC (stage IIIA/IIIB) Source: Eur Respir J 2002; 20: Suppl. 38, 399s Year: 2002
Is there any survival benefit of surgery after neoadjuvant chemoradiotherapy and persisting pn2/3 in stage III NSCLC? Source: Annual Congress 2009 - Diagnosis and treatment of lung cancer Year: 2009
Treatment of potentially resectable locoregional (stage III) non-small cell lung cancer Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment Year: 2005
Chemotherapy plus resection is not better than chemoradiotherapy for baseline unresectable stage IIIA-N2 NSCLC Source: ISSN=ISSN 1810-6838, ISBN=, page=380 Year: 2007
Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I–IIIA Source: Eur Respir Rev 2015; 24: 340-355 Year: 2015
Survival and postoperative complication after neoadjuvant therapy in resectable stage IIIA-N2 non-small cell lung cancer: a balancing exercise Source: Eur Respir J 2003; 22: Suppl. 45, 31s Year: 2003
A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003
Combination of neoadjuvant and adjuvant chemotherapy in marginally resectable IIIA nonsmall cell lung cancer (NSCLC): long-term follow up Source: Eur Respir J 2006; 28: Suppl. 50, 772s Year: 2006
Postoperative adjuvant treatment in stage III NSCLC Source: Eur Respir J 2007; 30: Suppl. 51, 434s Year: 2007
Long-term follow-up comparing postoperative chemotherapy or radiotherapy and surgery with surgery alone in resectable nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 131s Year: 2001
Treatment of unresectable locoregional (stage III) non-small cell lung cancer Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment Year: 2005
Phase I/II study of biweekly docetaxel/cisplatin with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer Source: Annual Congress 2005 - Chemotherapy and palliative care Year: 2005
Stage IIIA-N2 non-small cell lung cancer (NSCLC): comparison of prognostic factors in 257 patients treated with surgery (S) versus induction chemotherapy plus surgery (IC+S) Source: Eur Respir J 2002; 20: Suppl. 38, 597s Year: 2002
Selective adjuvant chemotherapy according to in-vitro chemoresistance test: Long term follow up of patients with resectable non-small cell lung cancer (NSCLC) stage IIIA Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010
Factors predicting complete surgical resection after induction chemotherapy in patients with initially unresectable non-small cell lung cancer (NSCLC) treated in a randomised trial Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003
Role of chemotherapy in stage III non-small cell lung cancer (NSCLC): adjuvant or induction? Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer Year: 2006
Impact of neoadjuvant therapies on surgical indications and early postoperative outcome Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts Year: 2005
Survival after induction chemotherapy and surgery in N2 (mediastinoscopy) NSCLC patients Source: Annual Congress 2009 - Management of thoracic malignancies Year: 2009